Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.

about

Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma.

P2860

Q41717532-DDB1527B-2E0C-4A25-B0E8-22FED69DDD9D

P2860

Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.

Item

http://www.wikidata.org/entity/Q40498334

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Genetic Modifiers of Progressi ...... ne Tyrosine Kinase Inhibitors.

@en

type

Item

label

Genetic Modifiers of Progressi ...... ne Tyrosine Kinase Inhibitors.

@en

prefLabel

Genetic Modifiers of Progressi ...... ne Tyrosine Kinase Inhibitors.

@en

P1476

Genetic Modifiers of Progressi ...... ne Tyrosine Kinase Inhibitors.

@en

P2093

Chao A Hsiung

http://www.w3.org/2001/XMLSchema#string

Chien-Jen Chen

http://www.w3.org/2001/XMLSchema#string

Chih-Yi Chen

http://www.w3.org/2001/XMLSchema#string

Chung-Hsing Chen

http://www.w3.org/2001/XMLSchema#string

Fang-Yi Lo

http://www.w3.org/2001/XMLSchema#string

Gee-Chen Chang

http://www.w3.org/2001/XMLSchema#string

I-Shou Chang

http://www.w3.org/2001/XMLSchema#string

James Chih-Hsin Yang

http://www.w3.org/2001/XMLSchema#string

Jih-Hsiang Lee

http://www.w3.org/2001/XMLSchema#string

Kuan-Yu Chen

http://www.w3.org/2001/XMLSchema#string

P2860

A user's guide to the encyclopedia of DNA elements (ENCODE)

Cancer pharmacogenomics: strategies and challenges

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Update in Lung Cancer 2014

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

P304

663-673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201602-0300OC

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

195

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27669169

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

P932

5363976

http://www.w3.org/2001/XMLSchema#string

Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.

about

P2860

P2860

Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932